|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 安罗替尼联合替吉奥二线治疗复发转移性食管鳞癌的临床疗效显示文摘目的探讨安罗替尼联合替吉奥二线治疗复发转移性食管鳞癌的临床疗效。方法选取2018年7月~2020年2月我院收治的一线紫杉醇联合铂类化疗失败的26例复发转移性食管鳞癌患者,给予患者12 mg安罗替尼口服,1次/d,联合50 mg替吉奥口服2次/d,连服2周,停药1周,共3周为1周期,分析其近期临床疗效、不良反应及中位无进展生存期。结果26例患者行安罗替尼联合替吉奥二线治疗后,其中无完全缓解者,部分缓解者(PR)6例,疾病稳定者12例,疾病进展者8例,客观缓解率为23.1%,疾病控制率(DCR)为69.2%,中位PFS为4.5月(95%CI:2.7-6.4)。单因素分析发现中高分化食管鳞癌患者较低分化者有更长的PFS(6.1月vs 1.9月,P<0.05)。Cox比例风险回归模型分析显示病理分化程度(HR=6.778,95%CI:1.997-23.012)是安罗替尼联合替吉奥治疗复发转移性食管鳞癌患者PFS延长的独立影响因素。安罗替尼联合替吉奥治疗的主要不良反应为乏力、高血压、手足综合症、蛋白尿、肝功能异常和腹泻等,多为Ⅰ~Ⅱ度。结论复发转移性食管鳞癌患者可从安罗替尼联合替吉奥二线治疗中获益,主要不良反应较轻,安全性高。 | 孙魏 邹玺 张微 胡守友 葛科伟 | 2021 | 南方医科大学学报2021，41，2： | 9 |
| 2 | 安罗替尼联合替吉奥二线治疗晚期食管癌的疗效及安全性显示文摘目的探讨安罗替尼联合替吉奥二线治疗晚期食管癌的疗效及安全性。方法选取2018年6月至2019年9月安徽医科大学附属巢湖医院收治的60例一线化疗后失败或缓解后再进展的晚期食管癌患者,采用随机数字表法分为观察组和对照组,各30例,观察组给予安罗替尼联合替吉奥方案,对照组给予单药替吉奥方案,每2周期进行疗效评价,分析两组有效率(ORR)、疾病控制率(DCR)、中位无进展生存时间(PFS),同时比较两组乏力、高血压、胃肠道反应、手足皮肤反应、口腔粘膜炎、骨髓抑制、肝功能损害、蛋白尿等不良反应差异。结果观察组ORR为23.3%(7/30),对照组ORR为10.0%(3/30),两组差异无统计学意义(P>0.05)。观察组DCR为76.7%(23/30),PFS为5.6个月;对照组DCR为46.7%(14/30),PFS为1.4个月,两组DCR、PFS差异均有统计学意义(P<0.05)。观察组高血压发生率高于对照组(P<0.05),两组余不良反应发生率差异均无统计学意义(P>0.05)。所有不良反应经对症处理后均缓解。结论安罗替尼联合替吉奥方案治疗晚期食管癌疗效及安全性尚可,不良反应可耐受,值得临床推广。 | 汪超 童斯浩 肖鑫 施险峰 | 2020 | 安徽医学2020，41，12： | 7 |
| 3 | Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma显示文摘Objective:Several anti-programmed cell death 1(anti-PD-1)antibodies have demonstrated potential efficacy in the treatment of advanced esophageal squamous cell cancer(ESCC).However,the response to subsequent chemotherapy after the failure of PD-1 blockade in ESCC patients has not been reported,and the optimal sequencing of immunotherapy and chemotherapy remains controversial.The aim of the present study was to evaluate responses to irinotecan-based subsequent chemotherapy in advanced ESCC patients who had progressed after treatment with camrelizumab(SHR-1210),a novel anti-PD-1 antibody.Methods:We retrospectively reviewed the medical records of patients with advanced ESCC treated with camrelizumab at a single institution.Consecutive patients who received subsequent irinotecan-based chemotherapy were selected for data collection and analysis.Results:Overall,a total of 28 patients were included.All patients had received at least two lines of systemic treatment prior to irinotecan salvage.The most common regimen that was administered after PD-1 blockade was irinotecan in combination with 5-fluorouracil(5-Fu)(or its derivatives),which was given to 19 patients.The objective response rate(ORR)and disease control rate(DCR)were 17.9%(5/28)and 64.3%(18/28),respectively,with 5(17.9%)patients achieving a partial response and 13(46.4%)having stable disease.The median progressionfree survival(PFS)was 3.18[95%confidence interval(95%CI),2.48-3.88]months and the median overall survival(OS)was 6.23(95%CI,4.71-7.75)months.No new safety issues,either immune-related or otherwise,were observed.Conclusions:Our results suggested that the response to irinotecan-based chemotherapy after PD-1 blockade in advanced ESCC patients appeared similar to that previously observed in patients who had not received PD-1 antibodies,and further study in larger cohorts or randomized trials is warranted to verify our observation. | Bo Zhang Xi Wang Qun Li Hongnan Mo Xingyuan Wang Yan Song Jianping Xu Tao Qu Jing Huang | 2019 | Chinese Journal of Cancer Research2019，31，6： | 3 |
| 4 | Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma显示文摘Objective:The mainstay treatment of esophageal squamous cell carcinoma(ESCC)involves chemotherapy and immunotherapy.However,alternative therapies are required for patients who are refractory or intolerant to existing therapies.Methods:In this single-arm,multicenter,open-label phase Ib study,30 patients received an intravenous infusion of SCT200,an antiepidermal growth factor receptor(EGFR)monoclonal antibody,6.0 mg/kg once a week for 6 weeks,followed by 8.0 mg/kg once every 2 weeks until disease progression or intolerable toxicity.The primary endpoint was the objective response rate(ORR).The secondary endpoints were progression-free survival(PFS),overall survival(OS),and safety.Results:Thirty patients were enrolled between July 2018 and May 2019.The ORR was 16.7%(95%CI:5.6%–34.7%).The median PFS and OS were 3.1 months(95%CI:1.5–4.3)and 6.8 months(95%CI:4.7–10.1),respectively.A numerical difference without any statistical significance in ORR was observed in patients with different EGFR expressions(≥50%:25.0%vs.<50%:0%,P=0.140)or TP53 mutation abundance(<10%:23.8%vs.≥10%:0%,P=0.286).Improved median PFS(3.4 vs.1.4 months,P=0.006)and OS(8.0 vs.4.2 months,P=0.027)were associated with TP53 mutation abundance of<10%.The most common treatment-related adverse events of grade 3 or 4(occurring in≥2 patients)were hypomagnesemia[7(23.3%)]and rash[2(6.7%)].No treatmentrelated death occurred.Conclusions:SCT200 monotherapy as the second-or further-line treatment for advanced ESCC showed favorable efficacy,with an acceptable safety profile.TP53 mutation abundance might serve as a potential predictive biomarker. | Ming Bai Meng Wang Ting Deng Yuxian Bai Kai Zang Zhanhui Miao Wenlin Gai Liangzhi Xie Yi Ba | 2022 | Cancer Biology & Medicine2022，19，3： | 2 |
| 5 | 复发转移食管鳞状细胞癌治疗进展显示文摘复发转移食管鳞状细胞癌(ESCC)预后差,治疗选择有限。以铂类为基础联合氟尿嘧啶或紫杉醇类的化疗为其标准一线治疗方案。以西妥昔单抗、帕尼单抗、尼妥珠单抗和吉非替尼等表皮生长因子受体抑制剂为主的分子靶向治疗药物,均未能改善晚期ESCC患者的生存。多靶点小分子酪氨酸激酶抑制剂安罗替尼应用于二线以上治疗可延长患者的中位无进展生存期。相较于化疗,免疫检查点抑制剂(如纳武利尤单抗、帕博利珠单抗、卡瑞利珠单抗)可显著延长一线化疗失败ESCC患者的总生存期,可作为标准二线治疗的选择。免疫治疗联合化疗或抗血管生成治疗应用于晚期ESCC一线治疗的研究也正在进行中。 | 池秀盈 王鸿彪 李植锋 林英城 | 2021 | 国际肿瘤学杂志2021，48，12： | 1 |
| 6 | 我院替吉奥超说明书使用调查分析显示文摘目的探讨替吉奥超说明书适应症使用情况并对其进行分析。方法调取本院2019年1~12月含有替吉奥的住院医嘱,根据食品药品监督管理局(SFDA)颁布的药品说明书对替吉奥超说明书用药情况进行分析。结果本院2019年含替吉奥的医嘱共256份,其中存在超说明书适应症使用的共139份(占比54.3%),主要用于食道癌、结直肠癌、胰腺癌和非小细胞肺癌的治疗。结论本院替吉奥超说明书适应症使用现象普遍存在,部分有较强循证依据,在临床应用中具有合理性,但使用时仍需权衡利弊。 | 赵晨 | 2020 | 临床医药文献电子杂志2020，7，67： | 0 |
| 7 | GDF11和活性氧在转移性口腔癌中的表达显示文摘目的探讨转移活性因子GDF11和活性氧在转移性口腔癌中的表达。方法随机选取2016年1月—2018年2月该院口腔癌患者56例,随机分为两组:一组有淋巴结转移的口腔癌组(转移性口腔癌组,20例),一组无淋巴结转移的口腔癌组(无转移性口腔癌组,36例)。在足量的10%甲醛中放置两组患者的一部分手术标本,在室温下固定,保证固定液完全覆盖组织,石蜡包埋后进行免疫组织化学实验;在无酶EP管中放置两组患者的另一部分手术标本,然后第一时间向液态氮中转移并储存,直到分析。将总RNA提取出来,对GDF11基因表达水平进行实时荧光定量检测。进行ROS实验,运用DCFH-DA荧光试验对两组患者的培养基活性氧(ROS)基因表达水平进行检测,然后统计分析两组患者的GDF11和活性氧表达。结果转移性口腔癌组患者的GDF11mRNA、ROS相对水平(6.7±1.4)%、(52.5±10.9)%均显著高于无转移性口腔癌组(3.2±1.0)%、(37.1±12.1)%,差异有统计学意义(t=4.303、6.965,P<0.05)。结论GDF11和活性氧在转移性口腔癌中的表达上升,值得临床充分重视。 | 孙丽美 | 2019 | 世界复合医学2019，5，8： | 0 |
| 8 | 阿帕替尼联合替吉奥姑息治疗晚期转移性食管鳞状细胞癌的近期效果观察显示文摘目的观察阿帕替尼联合替吉奥姑息治疗不能耐受联合化疗的晚期转移性食管鳞状细胞癌的近期效果。方法选择2019年1月—2020年6月不能耐受联合方案化疗的晚期转移性食管鳞状细胞癌26例,在患者知情同意的情况下,采用阿帕替尼联合替吉奥方案治疗,每2个周期治疗结束后,参考RECIST1.1实体瘤疗效评价标准评估疗效,同时观察毒副反应发生情况。结果26例治疗2个周期后,部分缓解7例、稳定11例、进展8例,客观有效率为26.9%(7/26),疾病控制率为69.2%(18/26)。10例疗效评估有效者完成6个周期联合治疗后,继续使用阿帕替尼联合替吉奥维持治疗,无进展生存时间最长达11个月,最短为6个月。26例治疗相关毒副反应均为Ⅰ~Ⅲ级,包括手足综合征、高血压、乏力、白细胞减少、血小板减少、贫血、恶心、腹泻、蛋白尿,未出现Ⅳ级毒副反应,上述毒副反应经对症治疗后均减轻或缓解,均能继续完成治疗。结论阿帕替尼联合替吉奥姑息治疗不能耐受联合化疗的晚期转移性食管鳞状细胞癌,显示出一定的有效性,毒副反应轻,耐受性良好。 | 鲁光平 杨春华 崔力 | 2022 | 临床误诊误治2022，35，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员